Despite recent advancements in the treatment of clinical and even preclinical T1DM—including the development of insulin analogues, automated insulin pumps, continuous glucose monitoring systems, closed-loop insulin delivery systems, and teplizumab (a humanized anti-CD3 monoclonal antibody approved for delaying the onset of clinically apparent T1DM)—managing the condition remains a significant burden for patients, requiring constant blood sugar monitoring and adjustments [6,7]. The gene discussed is INS; the disease is type 1 diabetes mellitus.